Status:

UNKNOWN

UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)

Lead Sponsor:

University Hospital, Angers

Conditions:

Non Alcoholic Fatty Liver Disease

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to assess UDFF performance (compared to MRI)

Eligibility Criteria

Inclusion

  • All patients who had hepatic ultrasound with available UDFF measurements and hepatic MRI (with steatosis quantification sequences) between 01/01/2022 and 31/09/2023 may be included.

Exclusion

  • chronic liver disease with a different etiology other than NAFL/NASH or mixed (hepatitis B or C, hemochromatosis, autoimmune hepatitis, Wilson's disease, cholestasic disease, alpha 1 antitrypsin deficiency),
  • decompensated cirrhosis (ascites, jaundice, encephalopathy, rupture of esophageal varices),
  • hepatocellular carcinoma.
  • opposition to the use of its data

Key Trial Info

Start Date :

March 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

October 15 2023

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT06080386

Start Date

March 1 2022

End Date

October 15 2023

Last Update

October 12 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Angers university hospital

Angers, France, 49000